# SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial

> **NCT05831202** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Galaxy Therapeutics INC** · enrollment: 279 (estimated)

## Conditions studied

- Intracranial Aneurysm

## Interventions

- **DEVICE:** The SEAL™ Saccular Endovascular Aneurysm Lattice System

## Key facts

- **NCT ID:** NCT05831202
- **Lead sponsor:** Galaxy Therapeutics INC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-06
- **Primary completion:** 2026-09-10
- **Final completion:** 2030-09-10
- **Target enrollment:** 279 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05831202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05831202, "SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05831202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*